Sensei Biotherapeutics (Sensei Biotherapeutics) Debt-to-Equity : 0.10 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Debt-to-Equity?

Sensei Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.44 Mil. Sensei Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.77 Mil. Sensei Biotherapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $64.90 Mil. Sensei Biotherapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sensei Biotherapeutics's Debt-to-Equity or its related term are showing as below:

SNSE' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.23 Med: 0 Max: 0.1
Current: 0.1

During the past 6 years, the highest Debt-to-Equity Ratio of Sensei Biotherapeutics was 0.10. The lowest was -0.23. And the median was 0.00.

SNSE's Debt-to-Equity is ranked better than
59.25% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs SNSE: 0.10

Sensei Biotherapeutics Debt-to-Equity Historical Data

The historical data trend for Sensei Biotherapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Debt-to-Equity Chart

Sensei Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.23

-0.01

0.02

0.08

0.10

Sensei Biotherapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial														0.08	0.08	0.09	0.10	0.10

Competitive Comparison of Sensei Biotherapeutics's Debt-to-Equity

For the Biotechnology subindustry, Sensei Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sensei Biotherapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sensei Biotherapeutics's Debt-to-Equity falls into.

Sensei Biotherapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sensei Biotherapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.439	+	3.769)	/	64.895
	=	0.10

Sensei Biotherapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.439	+	3.769)	/	64.895
	=	0.10

Sensei Biotherapeutics (NAS:SNSE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sensei Biotherapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sensei Biotherapeutics (Sensei Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (NAS:SNSE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

407:Germany 407:Germany

Address

1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210

Website

https://www.senseibio.com

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Executives

Stephanie Krebs	officer: Chief Business Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE MD 20850
John Celebi	director, officer: President & CEO	SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
James Peyer	director, 10 percent owner	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
Cambrian Biopharma Inc	10 percent owner, other: See Remarks	228 PARK AVENUE S., #66643, NEW YORK NY 10003
Apeiron Investment Group Ltd.	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Presight Sensei Co-invest Fund, L.p.	other: See Explanation of Responses	340 S. LEMON AVE., # 3391, WALNUT CA 91789
Van Der Horst Edward	officer: Chief Scientific Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 451 D STREET, SUITE 710, BOSTON MA 02210
Presight Co-invest Management, L.l.c.	10 percent owner	340 SOUTH LEMON AVENUE #3391, WALNUT CA 91789
Christian Angermayer	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Patrick Stephen Gallagher	officer: Chief Business Officer	66 HAROLD ST, BOSTON MA 02119
William R Ringo	director
Thomas G Ricks	director	H&S VENTURES LLC, 2101 EAST COAST HWY - 3RD FLOOR, CORONA DEL MAR CA 92625
Robert Hamilton Pierce	officer: Chief Scientific Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR.., STE. 125, ROCKVILLE MD 20850
Kristian Humer	director	C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jessie English	director	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR., STE. 125, ROCKVILLE MD 20850